Breaking Down Shanghai MicroPort Endovascular MedTech Co., Ltd. Financial Health: Key Insights for Investors

Investors tracking Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) will find this deep-dive indispensable as the company posted a striking quarter with revenue of CNY 300.35 million for Q3 2025 - up 64.68% year-on-year - while trailing twelve months revenue sits at CNY 1.25 billion (down 1.32% YoY) against 2024 annual sales of CNY 1.21 billion; profitability tells a mixed story with nine-month net income attributable to owners of CNY 429.06 million (down 22.46%), a TTM net profit margin of 34.33% (from 41.6%), EPS of CNY 3.54 versus CNY 4.49 a year earlier, and gross margin at 68.59%; the balance sheet reveals conservative leverage with total assets of CNY 4.46 billion, net cash of CNY 2.12 billion and a gearing ratio of 15.85% (interest coverage 197.23), liquidity remains robust-current ratio 4.75 and free cash flow of CNY 56.94 million-while valuation metrics show a TTM P/E of 31.41, forward P/E 19.29, P/S 9.41 and market cap of CNY 11.78 billion; key revenue drivers and risks include the Aortic Stents segment generating CNY 939.85 million in 2023 (over 60% of sales), strong domestic growth (CNY 1.10 billion, +30.94%) alongside faster-growing international sales (CNY 82.34 million, +56.19%), and a clean balance sheet reflected in book value per share of CNY 32.72 and net cash per share of CNY 17.57 that underpin planned R&D, international expansion and M&A exploration

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) - Revenue Analysis

• Q3 2025 revenue: CNY 300.35 million (+64.68% YoY)
• TTM revenue: CNY 1.25 billion (-1.32% YoY)
• Full-year 2024 revenue: CNY 1.21 billion (+1.61% vs. 2023)
• Aortic Stents (2023): CNY 939.85 million (+28.07% YoY for that segment)
• Geographic 2023 - Domestic China: CNY 1.10 billion (+30.94%); International: CNY 82.34 million (+56.19%)
• Revenue per employee: ~CNY 1.52 million (826 employees)

• Revenue composition shows heavy concentration in Aortic Stents-~77.7% of 2023 revenue (939.85M of 1.21B), indicating product-driven exposure.
• Domestic market remains the backbone; international sales are growing faster off a smaller base.
• Recent quarterly acceleration (Q3 2025) improves near-term outlook but TTM decline signals the need to monitor sustainability.

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) - Profitability Metrics

• Net income attributable to equity owners (9M ended Sep 30, 2025): CNY 429.06 million (down 22.46% YoY).
• EPS (9M ended Sep 30, 2025): CNY 3.54 (vs. CNY 4.49 in 9M 2024).
• TTM net profit margin: 34.33% (prior year: 41.6%).
• TTM operating margin: 36.34% (prior year: 42.58%).
• TTM gross profit margin: 68.59% (prior year: 70.91%).
• Return on equity (ROE): 9.33% (prior year: 10.99%).
• Return on assets (ROA): 6.12% (prior year: 6.29%).

• Margin contraction drivers: the TTM declines in gross, operating and net margins suggest increased cost pressures or pricing mix shifts despite still-high gross margin levels (68.59%).
• Profitability vs. capital efficiency: ROE and ROA declines indicate lower profitability retention relative to equity and asset base.
• Per-share impact: EPS decreased ~21.2% for the nine-month period, mirroring the fall in net income.

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) - Debt vs. Equity Structure

• Total assets: CNY 4.46 billion
• Total equity attributable to owners: CNY 3.85 billion
• Cash & cash equivalents: CNY 2.14 billion
• Total debt (short- + long-term): CNY 16.99 million
• Net cash position: CNY 2.12 billion

• The near-zero debt-to-equity ratio reflects negligible financial leverage relative to equity; shareholders' capital constitutes the dominant portion of the balance sheet.
• A gearing ratio of 15.85% indicates a conservative use of debt financing versus total capital employed.
• An interest coverage ratio of 197.23 implies operating earnings are overwhelmingly sufficient to cover interest expenses, reducing refinancing and default risk.
• Net cash of CNY 2.12 billion (cash CNY 2.14B minus debt CNY 16.99M) positions the company to fund operations, R&D or M&A without immediate reliance on external debt markets.
• Debt-to-EBITDA of 0.03 and debt-to-free cash flow of 0.30 both signal that existing debt levels are negligible relative to earnings and cash generation capability.

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) - Liquidity and Solvency

• Current ratio: 4.75 - ample short-term asset coverage of liabilities.
• Quick ratio: 4.31 - strong immediate liquidity excluding inventory.
• Working capital: CNY 2.31 billion - sizable cushion for operational needs.

• Cash generation vs. investment: Operating cash flow of CNY 361.36M against capex of CNY 304.41M yields a positive free cash flow of CNY 56.94M, indicating operations cover growth investments, albeit with a modest surplus.
• Balance-sheet strength: Net cash per share of CNY 17.57 combined with working capital of CNY 2.31B supports resilience during downturns and provides optionality for R&D, M&A, or shareholder returns.
• Distress risk and quality signals: An Altman Z-Score of 11.47 signals very low bankruptcy risk; however, a Piotroski F-Score of 3 flags potential issues in earnings quality, profitability trends, or balance-sheet improvements that merit closer monitoring.

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) - Valuation Analysis

• Market capitalization and enterprise value:
  • Market cap: CNY 11.78 billion
  • Enterprise value (EV): CNY 9.68 billion
• Equity valuation multiples:
  • Trailing twelve months (TTM) P/E: 31.41
  • Forward P/E: 19.29
  • Price-to-Sales (P/S): 9.41
  • Price-to-Book (P/B): 2.96
• Enterprise-value-based multiples:
  • EV/Revenue (EV/R): 7.73
  • EV/EBITDA: 19.01
  • EV/Free Cash Flow (EV/FCF): 169.95 - indicating valuation is high relative to reported free cash flow
• Shareholder return metric:
  • Dividend yield: 2.03%
  • Annual dividend per share: CNY 2.01

• Investor considerations:
  • A TTM P/E of 31.41 vs. forward P/E of 19.29 suggests expected earnings improvement baked into the forward multiple.
  • High P/S (9.41) and EV/R (7.73) reflect premium pricing relative to sales - common in medtech growth stories but increases sensitivity to execution risks.
  • EV/FCF at 169.95 flags limited free cash flow relative to enterprise value; monitor cash conversion and capex trends.
  • Dividend yield of 2.03% and CNY 2.01 annual DPS provide modest income but are secondary to growth/valuation dynamics for many investors.
• Further reading: Exploring Shanghai MicroPort Endovascular MedTech Co., Ltd. Investor Profile: Who's Buying and Why?

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) - Risk Factors

• Currency fluctuation exposure: roughly 20-28% of annual sales are invoiced or realized in non-CNY currencies (primarily EUR and USD), creating measurable P&L volatility when RMB moves against the euro and dollar.
• Rising financing costs: corporate borrowing rates for comparable Chinese medtech firms have risen by ~1.5 percentage points in recent cycles; this increases interest expense on variable-rate debt and raises refinancing risk for upcoming maturities.
• Product concentration: the flagship endovascular stent contributes over 60% of group revenue, concentrating commercial and regulatory risk in a single product family.
• Limited near-term diversification: no major new product launches have been reported since 2022, leaving revenue growth dependent on existing SKUs and geographic expansion.
• Procurement and pricing pressure: centralized procurement policies in China now account for an estimated 30-45% of hospital purchasing decisions in the company's core categories, pressuring margins and sale prices.
• Intense competition: competition from domestic and multinational device manufacturers keeps pricing and tender dynamics competitive; MicroPort's estimated domestic stent market share is in the mid-teens (≈15-20%), implying vulnerability to share erosion.

• Operational sensitivity: manufacturing or supply-chain disruptions affecting the stent line would have outsized revenue and gross-margin consequences because of the product's dominant share.
• FX hedging effectiveness: limited hedging or mismatch in currency denomination between costs (largely RMB) and revenues (EUR/USD) amplifies earnings volatility.
• Refinancing schedule: any near-term debt maturities should be reviewed-higher market rates may increase refinancing costs materially compared with historical averages.
• Regulatory risk: stent-related regulatory reviews in major markets (China, EU, US) could trigger temporary sales halts or additional clinical/labeling requirements.

• Revenue split by geography and currency (quarterly): track % EUR/USD vs. CNY receipts.
• Gross margin trends and tender win rates in centralized procurement cycles.
• R&D spend as % of revenue (pace of pipeline replenishment); product launch cadence.
• Debt maturity profile and effective interest rate (impact of +1.5% shift).

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) - Growth Opportunities

• International market expansion: recent product launches in Libya and rollout plans across MENA, Southeast Asia and selected European distributors.
• R&D-driven product diversification to reduce single-product concentration risk and extend into adjacent vascular and peripheral-device segments.
• Strategic partnerships and M&A exploration to acquire technology, bolster IP and accelerate time-to-market for next-generation devices.
• Targeting emerging markets with tailored pricing, local regulatory strategies and distribution partnerships to capture faster-growing demand pools.
• Using a strong cash position to fund capex, clinical trials and selective acquisitions while maintaining balance-sheet flexibility.
• Enhancing marketing & sales capabilities to strengthen brand recognition, KOL relationships and long-term customer loyalty.

• International launch playbook: leverage recent Libyan approvals and distributor agreements as a replicable template - focus on regulatory alignment, local clinical evidence and training programs for interventionalists.
• R&D pipeline priorities: invest in second-generation stent grafts, low-profile delivery systems and peripheral interventional platforms to increase TAM and cross-sell opportunities.
• M&A & partnerships roadmap: prioritize tuck-ins that add complementary IP or accelerate geographic registration (e.g., regulatory consultancy, local partners, manufacturing scale).
• Emerging markets strategy: combine tiered pricing, volume-driven supply agreements and local training centers to maximize uptake while protecting margins.
• Balance sheet use: allocate a portion of cash to fund pivotal trials, a portion to commercial expansion (market entry and salesforce expansion), and keep liquidity for selective acquisitions.
• Commercial & brand initiatives: expand KOL network, invest in digital marketing and outcome-focused clinical data generation to drive surgeon preference and hospital adoption.